A Short-Term, Multicenter, Randomized Double-Blind Dose Titration Study of the Efficacy and Anticholinergic Side Effects of Transdermal Compared to Immediate Release Oral Oxybutynin Treatment of Patients With Urge Urinary Incontinence

Davila, G. Willy; Daugherty, C.A.; Sanders, Steven W.

doi:10.1016/s0022-5347(05)66095-8

Cited by 197 publications

(75 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Three articles [19][20][21] not specifying adverse events, one article [22] not differentiating adverse events between antimuscarinic and placebo, six articles [23][24][25][26][27][28] not discriminating adverse events between different fixed dosages, and three articles [29][30][31] only comparing different releases within the same antimuscarinic and dosage were excluded. Thus, we finally included 69 trials including one report [66] with two different age strata ( Table 2, Data S2).…”

Section: Resultsmentioning

confidence: 99%

772 Adverse Event Assessment of Antimuscarinics for Treating Overactive Bladder: A Network Meta-Analytic Approach

Kessler¹,

Bachmann²,

Minder³

et al. 2010

European Urology Supplements

View full text Add to dashboard Cite

Background: Overactive bladder (OAB) affects the lives of millions of people worldwide and antimuscarinics are the pharmacological treatment of choice. Meta-analyses of all currently used antimuscarinics for treating OAB found similar efficacy, making the choice dependent on their adverse event profiles. However, conventional meta-analyses often fail to quantify and compare adverse events across different drugs, dosages, formulations, and routes of administration. In addition, the assessment of the broad variety of adverse events is dissatisfying. Our aim was to compare adverse events of antimuscarinics using a network meta-analytic approach that overcomes shortcomings of conventional analyses.

show abstract

Section: Resultsmentioning

confidence: 99%

772 Adverse Event Assessment of Antimuscarinics for Treating Overactive Bladder: A Network Meta-Analytic Approach

Kessler¹,

Bachmann²,

Minder³

et al. 2010

European Urology Supplements

View full text Add to dashboard Cite

show abstract

“…Dry mouth is a particularly bothersome side effect for patients that can limit therapy with oxybutynin IR. This side affect is less frequent with the ER and transdermal preparations (Anderson et al, 1999;Davila et al, 2001;Versi et al, 2000) Irritation and pruritus at the application site has been reported in approximately 15 percent of patients using transdermal oxybutynin and 5 percent using the topical gel. (Dmochowski et al, 2002) …”

Section: Oxybutyninmentioning

confidence: 99%

Diagnosis and Treatment of Overactive Bladder

Shaw¹,

Shaw²

2012

Urinary Incontinence

View full text Add to dashboard Cite

“…17 A short-term comparative study suggested that OXY-TDS had efficacy similar to that of immediate-release oral oxybutynin but was associated with a significantly lower incidence of dry mouth than the oral formulation. 18 A study in healthy volunteers further showed that the ratio of N-desethyloxybutynin (N-DEO) to oxybutynin plasma exposure levels was approximately 1.3 for OXY-TDS and approximately 4.0 for orally administered extended-release oxybutynin. 19 Subsequently, it was shown that healthy subjects receiving oxybutynin via transdermal delivery had significantly greater saliva production than those who received an oral formulation.…”

Section: Formulation Developmentmentioning

confidence: 99%

Development of oxybutynin chloride topical gel for overactive bladder

Lucente

De²

2011

RRU

View full text Add to dashboard Cite

Overactive bladder (OAB) is an age-related syndrome often associated with urinary incontinence. Symptoms of OAB, such as urgency, frequency, and nocturia, can be treated effectively with inhibitors of muscarinic acetylcholine receptors. Antimuscarinic agents promote relaxation of the detrusor muscle and may modulate afferent neuronal signals involved in the regulation of the micturition reflex. Despite the availability of an increasing number of oral antimuscarinic agents, treatment persistence among patients with OAB generally appears to be low. This may be attributed, at least in part, to the common occurrence of anticholinergic adverse effects, such as dry mouth, constipation, and dizziness. Oxybutynin is a well-established antimuscarinic agent that is available in a variety of formulations. Transdermal formulations have been developed to avoid the first-pass hepatic and gastrointestinal drug metabolism responsible for the anticholinergic adverse effects often observed with oral delivery of oxybutynin. Oxybutynin chloride topical gel (OTG) is a formulation of oxybutynin that was approved by the US Food and Drug Administration in January 2009. OTG was the result of a systematic evidence-based effort to develop a formulation that preserves the efficacy of oral oxybutynin formulations while eliminating most of their anticholinergic adverse effects. Additional emphasis was put on creating a transdermal formulation with minimal potential for application-site skin reactions. The formulation and pharmacokinetic properties of OTG are reviewed in the context of recently published efficacy and tolerability data from a large multicenter, placebo-controlled Phase III study.

show abstract

A Short-Term, Multicenter, Randomized Double-Blind Dose Titration Study of the Efficacy and Anticholinergic Side Effects of Transdermal Compared to Immediate Release Oral Oxybutynin Treatment of Patients With Urge Urinary Incontinence

Abstract: Transdermal delivery of oxybutynin resulted in comparable efficacy and a significantly improved anticholinergic side effect profile compared with oral administration in adults with urge urinary incontinence.

Cited by 197 publications

References 14 publications

772 Adverse Event Assessment of Antimuscarinics for Treating Overactive Bladder: A Network Meta-Analytic Approach

772 Adverse Event Assessment of Antimuscarinics for Treating Overactive Bladder: A Network Meta-Analytic Approach

Diagnosis and Treatment of Overactive Bladder

Development of oxybutynin chloride topical gel for overactive bladder

Contact Info

Product

Resources

About